S&P 500 Industrials Sector SEC Filings — May 20, 2026

20-05-2026

Red Cat Holdings, Inc. (RCAT) completed the acquisition of Quaze Technologies Inc., a developer of wireless power transfer technology for unmanned systems, on May 20, 2026. The acquisition addresses a key operational constraint—manual battery swaps and connector-based charging—by enabling autonomous recharging across air, land, and maritime domains. Quaze will operate as an independent business unit and maintain a platform-agnostic model, opening a new revenue channel from third-party systems while strengthening Red Cat's all-domain capabilities.

• · Quaze is based in Québec, Canada.
• · The QU6 electronic architecture enables large surfaces to function as wireless energy access points without requiring precise alignment, physical connectors, or direct contact.
• · The system can operate in the presence of debris, sand, ice, or snow.
• · Quaze’s technology has been demonstrated across aerial drones, ground systems, and autonomous underwater vehicles.
• · Red Cat expects Quaze to support expansion into maritime systems and multi-platform autonomy, including swarming, extended ISR missions, and autonomous deployment cycles.
• · The acquisition introduces a new revenue channel through integration into third-party systems, making Quaze a potential standard for wireless power across the unmanned systems ecosystem.

20-05-2026

Analog Devices Inc. (ADI) reported a strong Q2 FY2026 with revenue of $3.62B, up 37% YoY from $2.64B, and net income of $1.18B, more than doubling from $570M. The Industrial segment surged 56% YoY and Communications grew 79%, while Automotive revenue was nearly flat at +2% YoY. The company also recorded $29.1M in new employee severance costs under global repositioning actions during the quarter.

• · Distributor channel revenue was $2.07B (57% of total) in Q2 FY2026, up from $1.48B (56%) in Q2 FY2025.
• · Direct customer revenue was $1.52B (42% of total) in Q2 FY2026, up from $1.13B (43%) in Q2 FY2025.
• · Accrued special charges for global repositioning actions stood at $13.4M at May 2, 2026, down from $31.2M at January 31, 2026, after $17.9M in severance payments during Q2.
• · Total assets measured at fair value were $2.23B as of May 2, 2026, including $703M in government/institutional money market funds and $398M in corporate obligations (Level 2).
• · Total liabilities measured at fair value were $33.9M, consisting of forward foreign currency exchange contracts ($10.0M) and interest rate derivatives ($23.9M).
• · Other comprehensive income for Q2 FY2026 was $2.3M, driven by foreign currency translation gains ($1.3M) and derivative gains ($0.6M).
• · Provision for income taxes increased to $148.5M in Q2 FY2026 from $56.2M in Q2 FY2025, reflecting higher pre-tax income.

20-05-2026

Philip Morris International announced the appointment of Massimo Andolina as Group CFO, effective August 1, 2026, succeeding Emmanuel Babeau, who will remain as Strategic Advisor until March 31, 2027. Andolina, previously President of the Europe Region, led robust top- and bottom-line growth in the region, while Babeau oversaw strong financial performance and the acquisition of Swedish Match during his tenure. The smoke-free business accounted for 43% of Q1 2026 net revenues, but the company faces ongoing risks including regulatory restrictions, excise tax increases, and geopolitical instability.

• · Andolina joined PMI in 2008 and served as SVP Global Operations from 2018 to 2023, leading a team of over 30,000 people.
• · Babeau was appointed CFO in May 2020 and led the acquisition of Swedish Match in 2022.
• · Smoke-free products are available in over 105 markets and used by over 43 million legal-age consumers as of December 31, 2025.
• · The U.S. FDA has authorized marketing of Swedish Match's General snus and ZYN nicotine pouches, as well as versions of IQOS devices and consumables.
• · Andolina holds a Master of Science in Mechanical and Industrial Engineering from the University of Palermo and an MBA from IMD in Lausanne.

20-05-2026

CHOICE HOTELS INTERNATIONAL INC announced a leadership transition on May 20, 2026, with CEO Patrick S. Pacious stepping down effective immediately and Dominic E. Dragisich appointed as Interim CEO. Pacious will serve as an advisor through August 31, 2026, and remains a director nominee. The Board has initiated a search for a permanent CEO. The transition includes a separation agreement with Pacious providing cash severance of 200% of base salary and target bonus, continued equity vesting, and benefits through 2037. Dragisich receives a $500,000 cash bonus and $500,000 RSU award. The filing does not contain financial results or period-over-period comparisons.

• · Pacious's separation agreement includes cash severance equal to 200% of base salary and target bonus, plus pro rata bonus for 2026.
• · Pacious will continue vesting in equity awards for two years post-separation, except 2022 RSUs which vest pro rata.
• · Health insurance premium payments for Pacious from Separation Date until September 30, 2032.
• · Pacious remains a nominee for election at the Annual Meeting.
• · Dragisich previously served as CFO from March 2017 to September 2023.

20-05-2026

Global Innovative Platforms Inc. reported its first-ever revenue of $106,500 for Q2 FY2026, compared to zero in the prior year, driven by initial product sales. However, the company continues to incur significant operating losses, with a net loss of $151,386 for the quarter, nearly unchanged from $151,351 a year ago. Operating expenses surged 73% to $256,062, primarily due to higher general and administrative costs, while cash used in operations improved to $136,797 from $311,606 in the prior six-month period.

• · General and administrative expenses increased 123% to $203,187 in Q2 FY2026 from $91,046 in Q2 FY2025.
• · Research and development expenses decreased 48% to $1,825 in Q2 FY2026 from $3,541 in Q2 FY2025.
• · Net cash provided by financing activities was $514,354 for six months ended March 31, 2026, up from $467,500 in the prior period.
• · The company converted $175,488 of product development costs to fixed assets during the six months.
• · Weighted average common shares outstanding increased to 46,716,156 in Q2 FY2026 from 38,427,463 in Q2 FY2025.
• · As of March 31, 2026, the company had an accumulated deficit of $1,456,279.

20-05-2026

Ionetix Corp filed an amendment (8-K/A) to its original Form 8-K to include unaudited interim financial statements of Legacy Ionetix for the three months ended March 31, 2026 and 2025, along with pro forma combined financial information. Revenue declined sharply by 58.6% YoY to $1.071M, while net loss widened to $6.941M from $2.391M in the prior-year period, driven by a $2.535M other expense (vs. $2.118M other income in 2025). However, operating expenses decreased 19.2% YoY, and cash used in operations improved to $2.213M from $4.385M.

• · Cash used in operating activities improved to $2.213M in Q1 2026 from $4.385M in Q1 2025.
• · Total liabilities decreased 14.4% to $19.366M as of March 31, 2026 from $22.636M at December 31, 2025, primarily due to conversion of SAFE liability ($4.086M to $0).
• · Redeemable convertible preferred stock increased by $6.668M due to conversion of SAFEs to Series F preferred stock.
• · Stockholders' deficit widened to $182.719M from $178.851M, driven by the net loss.
• · Property and equipment, net decreased slightly to $26.353M from $27.214M.
• · Short-term debt increased to $6.490M from $5.753M.
• · Non-cash loss on issuance of SAFEs and common stock warrants was $2.217M in Q1 2026.
• · The company had $129K cash on hand as of March 31, 2026, down from $279K at year-end 2025.

20-05-2026

NanoViricides, Inc. (NNVC) announced a registered direct offering of approximately $2 million with a single institutional investor, involving 1,333,334 common shares (or pre-funded warrants) and accompanying warrants exercisable at $1.75 per share for three years. The offering is expected to close on May 18, 2026, with D. Boral Capital LLC as placement agent. While the capital raise provides near-term funding, the relatively small gross proceeds of ~$2 million highlight the company's ongoing need for additional capital to support clinical-stage operations.

• · Each whole warrant has an exercise price of $1.75 per share and expires three years from issuance.
• · The offering is conducted under an effective shelf registration statement on Form S-3 (Registration No. 333-271706), declared effective on May 22, 2023.
• · NV-387 has received Orphan Drug Designation from the FDA, potentially providing 7 years market exclusivity, tax credits, and fee exemptions upon approval.
• · NV-387 has shown efficacy in lethal animal infection models for Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

20-05-2026

Lake Shore Bancorp, Inc. held its Annual Meeting of Shareholders on May 20, 2026, where all four proposals were approved. Shareholders elected three Class Three directors (Michelle M. DeBergalis, Jack L. Mehltretter, Dennis S. Pollack) to terms expiring in 2029, approved the non-binding advisory resolution on executive compensation, chose a one-year frequency for future advisory votes, and ratified Yount, Hyde & Barbour, P.C. as the independent auditor for fiscal year 2026. The company will include the advisory vote on executive compensation annually until the next required frequency vote.

• · Director vote results: DeBergalis received 4,345,346 votes for and 468,365 withheld; Mehltretter received 4,390,548 for and 423,163 withheld; Pollack received 4,690,640 for and 123,071 withheld. All had 1,119,394 broker non-votes.
• · Advisory vote on executive compensation: 3,988,849 for, 486,649 against, 338,213 abstained, with 1,119,394 broker non-votes.
• · Frequency vote: 4,464,166 chose 1 year, 85,825 chose 2 years, 173,803 chose 3 years, 89,917 abstained, with 1,119,394 broker non-votes.
• · Ratification of auditor: 5,895,190 for, 26,814 against, 11,101 abstained.

20-05-2026

Longeveron Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on July 1, 2026. Key proposals include electing three directors, increasing authorized Class A common stock, authorizing a reverse stock split (1:2 to 1:20), amending the 2021 Incentive Award Plan to increase authorized shares, and ratifying CBIZ CPAs P.C. as independent auditor for fiscal year 2026. The filing does not disclose financial results or performance metrics, so no positive or negative trends can be assessed from this document alone.

• · Record date for voting is May 11, 2026.
• · Class A common stock holders have 1 vote per share; Class B common stock holders have 5 votes per share.
• · A quorum requires at least one-third of issued and outstanding shares representing a majority of votes entitled to be cast.
• · Proposal 2 seeks to increase authorized Class A common stock shares (amount not specified).
• · Proposal 3 authorizes a reverse stock split at a ratio ranging from 1:2 to 1:20, with exact ratio set by the Board.
• · Proposal 4 seeks to increase shares authorized under the 2021 Incentive Award Plan (amount not specified).
• · Proposal 6 allows adjournment if needed to solicit additional votes for Proposals 2 or 3.

20-05-2026

Analysis unavailable

20-05-2026

Willamette Valley Vineyards, Inc. appointed John Hazlett as Chief Financial Officer effective May 20, 2026, replacing John Ferry who announced his retirement on February 12, 2026. Mr. Hazlett will receive a base salary of $216,000 per year and is eligible for an annual performance-based incentive of up to $24,000. The transition period for Mr. Ferry has not yet been determined.

• · Mr. Hazlett, 51, has served as founding partner of Trailwise Advisory Services since January 2025.
• · He previously served as CFO of RENA Technologies North America (Dec 2021–Dec 2024) and Climax Portable Machine Tools (Mar 2018–Mar 2020).
• · He holds an MBA from Baldwin Wallace University and a BS in Accounting and Finance from Bowling Green State University, and maintains an active CPA license in Ohio.
• · Mr. Hazlett has no family relationships with any current director, director nominee, or executive officer of the Company.
• · The employment agreement is dated May 19, 2026, and performance goals will be established annually by the Company’s President.

20-05-2026

Deep Fission, Inc. filed an S-1 registration statement on May 20, 2026, for an IPO of 6,000,000 shares of common stock at an anticipated price range of $24.00 to $26.00 per share. The company has applied to list on Nasdaq under the symbol 'FISN'.

• · The filing date is May 20, 2026.
• · The anticipated public offering price range is $24.00 to $26.00 per share.
• · The company is a Delaware corporation with principal executive offices in Berkeley, California.
• · The common stock has no established public trading market.

20-05-2026

Brand Engagement Network Inc. (BNAI) announced on May 19, 2026, that its wholly owned subsidiary Datum Point Labs was granted U.S. Patent No. 12,633,027 for 'Systems and Methods for Gesture Generation From Text.' The patent covers an AI system that generates realistic human gestures and body movements from text input, enabling lifelike avatar interactions. This strengthens BEN's intellectual property portfolio in digital humans, virtual assistants, robotics, gaming, and metaverse applications.

• · The patent was granted on May 19, 2026, and the 8-K was filed on May 20, 2026.
• · The patent describes a multi-stage AI architecture that translates natural language into internal action representations and then into coordinated body positions and gesture sequences.
• · BEN believes the patent has broad applications in digital humans, virtual assistants, robotics, humanoid systems, gaming, entertainment, immersive metaverse environments, AI-based education and training, and telepresence or customer interaction platforms.

20-05-2026

AITX announced that its subsidiary RAD has signed an agreement with a global healthcare organization. The filing is a Form 8-K furnished under Item 8.01, with the press release attached as Exhibit 99.1. No financial terms or specific performance metrics were disclosed, and the filing is not deemed filed for Exchange Act purposes.

• · The agreement is with a global healthcare organization (name not disclosed).
• · The press release was issued on May 20, 2026.
• · The filing is furnished under Item 8.01 and is not deemed filed under Section 18 of the Exchange Act.

20-05-2026

GEN Restaurant Group, Inc. filed a universal shelf registration statement (Form S-3) with the SEC on May 19, 2026, to register up to $50,000,000 of its Class A common stock for potential future offerings. The company, which operates 59 company-owned restaurants across the U.S. and six stores in South Korea, is classified as both an emerging growth company and a smaller reporting company, allowing it to follow reduced disclosure requirements. As of May 18, 2026, the stock's last reported sale price on Nasdaq was $2.30 per share.

• · The company was incorporated as a Delaware corporation on October 28, 2021, and prior to its IPO and reorganization, it did not conduct any activities other than those incidental to formation.
• · GEN Restaurant Group is an Asian casual dining concept founded in 2011 by two Korean immigrants, with the first restaurant opening in September 2011.
• · The company qualifies as an emerging growth company until the earlier of: fiscal year with total annual gross revenue of $1.235B or more, five years after IPO completion, issuance of more than $1B in nonconvertible debt in three years, or becoming a large accelerated filer (non-affiliate market value exceeding $700M).
• · As a smaller reporting company, GEN is permitted to provide only two years of audited financial statements and simplified executive compensation disclosure.
• · The company has elected to use the extended transition period for complying with new or revised accounting standards, which may make its financial statements not comparable to companies that comply with public company effective dates.

20-05-2026

WidePoint Corp reported Q1 2026 revenue of $7.5M, up 8% YoY from $6.9M, driven by growth in cybersecurity and telecom services. However, net loss widened to $1.2M from $0.9M in Q1 2025, impacted by higher operating expenses. The company also announced a registered direct offering of common stock for gross proceeds of $5.0M.

• · Cybersecurity and telecom services drove revenue growth.
• · Higher operating expenses contributed to widened net loss.
• · Registered direct offering of common stock for gross proceeds of $5.0M.

20-05-2026

Entravision Communications Corp. mutually terminated its Cooperation Agreement with Alexandra Seros and related trusts on May 18, 2026. The agreement had been in place since May 4, 2023, and governed board nomination rights and stock ownership commitments. As a result, all rights and obligations under the agreement have been terminated, but Thomas Strickler (originally nominated under the agreement) will remain on the board. No financial figures are disclosed in this filing.

• · The Cooperation Agreement was originally dated May 4, 2023.
• · The termination is mutual between the Company and the Stockholders.
• · Thomas Strickler will remain on the board despite the termination of the agreement.

20-05-2026

S&P Global Inc. announced the pricing of a private offering of $2.0 billion aggregate principal amount of senior notes by Mobility Global Inc., a holding company for its Mobility division, ahead of the planned spin-off. The offering includes $650 million of 5.050% notes due 2029, $650 million of 5.450% notes due 2031, and $700 million of 6.050% notes due 2036, with closing expected on May 29, 2026. The notes are being offered to qualified institutional buyers and non-U.S. persons in exempt transactions.

• · The offering is exempt from registration under Rule 144A and Regulation S.
• · The notes are being issued by Mobility Global Inc., a recently formed holding company for the Mobility division.
• · The spin-off of the Mobility division is intended to be completed via a distribution to S&P Global shareholders.
• · The press release was issued pursuant to Rule 135c of the Securities Act.

20-05-2026

On May 15, 2026, Bed Bath & Beyond appointed CFO Brian LaRose as principal accounting officer, succeeding Leah Putnam, and appointed Tamara Ward as a new director, effective immediately. Ms. Ward will chair the Compensation Committee and serve on the Audit Committee, receiving an annual cash retainer of $75,000 and restricted stock units valued at $165,000. No financial performance metrics or period-over-period comparisons are included in this filing.

• · Brian LaRose's appointment as principal accounting officer is effective May 15, 2026, with no arrangements or understandings with any other person.
• · Tamara Ward's term as director expires at the 2027 annual meeting or earlier upon death, resignation, or removal.
• · Ms. Ward will enter into the Company's standard form of indemnification agreement.
• · No family relationships or material interests in transactions were reported for either appointee.

20-05-2026

Storebrand Asset Management AS filed its 13F-HR for the period ending December 31, 2025, reporting $37.24 billion in total holdings across 776 positions. The filing shows a diversified portfolio with top holdings in Visa Inc. ($606.96M), Tesla Inc. ($698.62M), Waste Management Inc. ($323.48M), and Wells Fargo & Co. ($163.33M). No prior period data is provided, so period-over-period comparisons are not available.

20-05-2026

Oragenics, Inc. filed a DEF 14A proxy statement for the 2025 Annual Meeting of Shareholders to be held virtually on June 29, 2026. Key proposals include election of six directors (Proposal 1), a non-binding advisory vote on executive compensation (Proposal 2), authorization for the Board to effect a reverse stock split at a ratio between 1:2 and 1:50 within one year of shareholder approval (Proposal 3), and ratification of Cherry Bekaert LLP as independent auditors for FY2026 (Proposal 4). The company had 4,511,957 shares of common stock outstanding as of the record date of April 27, 2026, with additional Series F and Series H convertible preferred shares outstanding but non-voting.

• · The Annual Meeting will be held virtually on June 29, 2026 at 10:00 a.m. Eastern Time.
• · Proxy materials first disseminated to shareholders on or about May 20, 2026.
• · Shareholders of record as of April 27, 2026 are entitled to vote.
• · The reverse stock split ratio range authorized would be between 1:2 and 1:50, with the exact ratio determined by the Board and announced publicly.
• · The Series F and Series H Convertible Preferred Stock are not entitled to vote at the Annual Meeting.
• · If all Series H warrants were exercised and the underlying Series H preferred converted, approximately 23,925,000 additional common shares could be issued.
• · The board recommends a vote FOR all four proposals.
• · The fiscal year ended December 31, 2025 annual report is available alongside the proxy statement.

20-05-2026

West Pharmaceutical Services filed an 8-K/A amendment disclosing that a material cybersecurity attack was detected on May 4, 2026, with data exfiltration and system encryption. The company has restored core systems, resumed manufacturing and shipping at all sites, and is now fully operational globally; no unauthorized activity has been observed since May 5, 2026. Based on the investigation to date, the company believes the incident has not had and is not reasonably likely to have a material impact on its 2026 second-quarter and full-year financial guidance.

• · The cybersecurity incident involved data exfiltration by an unauthorized party and encryption of certain systems.
• · Initial detection of the intrusion occurred on May 4, 2026; the company promptly activated incident response protocols, including taking systems offline globally, notifying law enforcement, and engaging external cyber-forensic experts.
• · No unauthorized activity or access has been observed since May 5, 2026.
• · The company's investigation into the nature and scope of the incident is continuing, including regarding the extent of data affected.
• · The company believes the incident has not had and is not reasonably likely to have a material impact on its 2026 second-quarter and full-year financial guidance.

20-05-2026

Southside Bancshares Inc announces an amendment to its Restated Certificate of Formation, approved by shareholders and effective upon filing with the Texas Secretary of State. The amendment increases the authorized capital stock from a prior amount to 88,000,000 total shares, comprising 80,000,000 shares of common stock ($1.25 par value) and 8,000,000 shares of preferred stock (no par value). The filing provides standard authorization for the Board to designate series of preferred stock, with no financial results or period-over-period comparisons included.

• · First Amendment to Restated Certificate of Formation filed under Texas Business Organizations Code
• · Original formation date of the corporation: August 11, 1982 (file number 61819600)
• · Common stock par value set at $1.25 per share; preferred stock has no par value
• · Amendment became effective upon filing with the Texas Secretary of State on or around May 20, 2026
• · Board of Directors retains authority to designate series, preferences, and rights of preferred stock

20-05-2026

Diamondback Energy announced the transition of Travis D. Stice from Executive Chairman to non-executive Chairman effective May 20, 2026, as part of a previously disclosed leadership plan. At the 2026 Annual Meeting, stockholders elected 13 directors, approved executive compensation on an advisory basis, and ratified Grant Thornton as auditor. The board also determined to hold future advisory votes on executive compensation annually.

• · Travis Stice received 245,001,012 votes for and 4,645,408 against his election as director.
• · Proposal 2 (advisory vote on executive compensation) received 245,941,011 votes for and 3,547,122 against.
• · Proposal 3 (frequency of advisory vote) resulted in 246,338,007 votes for 1 year, 371,078 for 2 years, and 2,888,098 for 3 years.
• · Proposal 4 (ratification of Grant Thornton) received 263,223,128 votes for and 1,308,991 against.
• · The next advisory vote on frequency of future advisory votes will be no later than the 2032 annual meeting.

20-05-2026

Grayscale Bittensor Trust (TAO) issued 211,900 Shares in private placements to accredited investors since its last 8-K filing, raising approximately $1,149,569 in TAO tokens. The shares were issued at varying prices based on NAV per Share, with Grayscale Securities acting as Authorized Participant and potential underwriter, though no underwriting discounts or commissions were paid. Total shares outstanding increased to 2,397,300 as of May 20, 2026.

• · Shares were issued to accredited investors under Rule 506(c) of Regulation D, exempt from SEC registration.
• · Grayscale Securities may be deemed an 'underwriter' under Section 2(a)(11) of the Securities Act due to periodic share creation and distribution.
• · No underwriting discounts or commissions were paid to Grayscale Securities for these sales.
• · The trust is an emerging growth company and has not elected to use the extended transition period for new financial accounting standards.

20-05-2026

TREASURE GLOBAL INC (TGL) reported a net loss of $2.32M for Q3 FY2026 (three months ended March 31, 2026), compared to net income of $1.26M in the same quarter last year, driven by a sharp decline in gross profit to just $6,415 from $486,283. Revenue grew 125% YoY to $1.50M, but cost of revenues surged to $1.49M, nearly matching revenue. For the nine-month period, the net loss widened to $7.56M from a prior-year net income of $0.08M, while cash and cash equivalents increased significantly to $2.91M from $0.24M at June 30, 2025, primarily due to financing activities.

• · Total operating expenses for the three months ended March 31, 2026 were $4,192,751, up from $529,692 in the prior year period, driven largely by a $3,811,991 general and administrative expense.
• · The company recorded a long-lived assets impairment of $3,044,877 in the nine months ended March 31, 2026.
• · Allowance for credit losses was $3,434,741 for the nine months ended March 31, 2026, compared to $90,480 in the prior year period.
• · Net cash used in operating activities for the nine months ended March 31, 2026 was $5,191,149, improving from $5,817,360 in the prior year period.
• · The company issued 1,675,725 common shares as of March 31, 2026, up from 207,470 as of June 30, 2025, reflecting significant equity financing activities including share purchase agreements, direct offerings, and warrant exercises.
• · Derivative liabilities increased to $1,165,795 as of March 31, 2026 from $383,886 as of June 30, 2025.
• · The company had no intangible assets as of March 31, 2026, down from $3,044,877 as of June 30, 2025, due to impairment.
• · Basic and diluted loss per share was $(1.39) for the three months ended March 31, 2026, compared to income per share of $21.79 in the prior year period.
• · The company effected a 1-for-50 reverse stock split on April 7, 2025 and a 1-for-20 reverse stock split on December 5, 2025.

20-05-2026

Twin Vee PowerCats Co. delivered a notice of non-renewal to CEO Joseph Visconti, whose employment agreement will expire on July 23, 2026. After that date, Visconti will continue as CEO, Interim CFO, and President on an at-will basis. The non-renewal was not due to any disagreement.

• · The Employment Agreement was effective July 23, 2021.
• · The Initial Term expires on July 23, 2026.
• · The notice was delivered on May 17, 2026.
• · The filing was made on May 20, 2026.

20-05-2026

INOVIO PHARMACEUTICALS, INC. adopted amendments to its Amended and Restated Bylaws on May 19, 2026, primarily to clarify the roles and meeting presidencies of the Chairman of the Board, Lead Independent Director, Chief Executive Officer, and President. The amendments formalize the Lead Independent Director position with specific duties, including agenda setting and presiding over independent director meetings and CEO evaluation sessions. The changes also update the duties of the CEO and President, specifying their presiding roles in the absence of the Chairman and Lead Independent Director.

• · The amendment adds a new Section 3.11 to Article III, formally defining the Lead Independent Director role with seven specific duties.
• · Section 3.5(e) establishes a clear order of precedence for presiding over board meetings: Chairman, Lead Independent Director, CEO (if a director), President (if a director), or a chairman chosen by a majority of directors.
• · Section 3.10 clarifies that the Chairman of the Board is not automatically an officer unless expressly designated by the Board.
• · Section 4.2(b) and (c) update the duties of the CEO and President, including their presiding roles at stockholder and board meetings in the absence of the Chairman and Lead Independent Director.

20-05-2026

MacroGenics held its 2026 Annual Meeting on May 19, 2026, with approximately 58% of outstanding shares represented. Stockholders approved all four proposals: election of three Class I directors, ratification of Ernst & Young as independent auditor for FY2026, advisory approval of named executive officer compensation, and an amendment to the 2023 Equity Incentive Plan to increase available shares by 1,250,000. Notably, the compensation proposal and equity plan amendment received significant broker non-votes (9,397,708 each), and the equity plan amendment had a relatively high number of against votes (1,671,102), indicating some shareholder dissent.

• · Proposal 1 (Director Elections): Scott Koenig received 26,353,906 for and 992,399 withheld; Federica O'Brien received 26,467,370 for and 878,935 withheld; Eric Risser received 27,174,501 for and 171,804 withheld. All had 9,397,708 broker non-votes.
• · Proposal 2 (Auditor Ratification): 36,689,683 for, 40,552 against, 13,778 abstain, 0 broker non-votes.
• · Proposal 3 (Say-on-Pay): 26,624,952 for, 526,125 against, 195,228 abstain, 9,397,708 broker non-votes.
• · Proposal 4 (Equity Plan Amendment): 25,600,112 for, 1,671,102 against, 75,091 abstain, 9,397,708 broker non-votes.
• · Record date for the meeting was March 27, 2026.

20-05-2026

COPT Defense Properties held its 2026 Annual Meeting on May 14, 2026, where shareholders elected eight trustees, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as the independent auditor. All proposals passed with strong shareholder support, though the ratification of PwC received a notable 6.9% against vote (7,015,739 shares).

• · All eight trustee nominees were elected with at least 95.5% of votes cast in favor (excluding broker non-votes).
• · The highest against vote among trustees was for Robert L. Denton, Sr. with 5,287,283 shares against (5.0% of votes cast).
• · Broker non-votes totaled 1,640,004 shares for all trustee elections and Proposal 2.
• · Proposal 3 (PwC ratification) had no broker non-votes, with 7,015,739 shares against (6.9% of votes cast).

20-05-2026

Bank of the James Financial Group held its Annual Meeting on May 19, 2026, with 78.65% of outstanding shares represented. Shareholders elected four Group Two directors, ratified Elliott Davis as auditor for 2026, and approved non-binding advisory say-on-pay compensation. All proposals passed with strong support, though director elections showed notable withheld votes for three of the four nominees.

• · Record date for shareholder determination was March 23, 2026.
• · Proposal 1 (Director Elections): Robert R. Chapman III received 2,435,558 votes for and 42,840 withheld; Julie P. Doyle received 2,177,449 for and 300,949 withheld; Lydia K. Langley received 2,176,380 for and 302,018 withheld; Augustus A. Petticolas, Jr. received 2,156,391 for and 322,007 withheld.
• · Proposal 2 (Auditor Ratification): 3,565,490 votes for, 4,655 against, 3,260 abstentions.
• · Proposal 3 (Say-on-Pay): 2,403,289 votes for, 31,082 against, 44,027 abstentions.
• · Broker non-votes on director elections and say-on-pay were 1,095,007 shares.

20-05-2026

Republic Bancorp, Inc. announced its second quarter 2026 cash dividend on May 20, 2026, via a news release. The dividend amount is not specified in the filing.

• · The dividend announcement was made under Item 7.01 Regulation FD Disclosure.
• · The news release is attached as Exhibit 99.1.
• · The filing date is May 20, 2026.

20-05-2026

ConnectOne Bancorp, Inc. held its Annual Meeting on May 19, 2026, where shareholders elected 15 directors, approved the 2026 Equity Incentive Plan, and ratified the independent auditor. The board also appointed Elizabeth Magennis as President of the Registrant, while Frank Sorrentino continues as Chairman and CEO. All proposals passed with strong support, though broker non-votes were significant at 6,162,210 shares.

• · Proposal 1: All 15 directors were elected with votes For ranging from 34,914,271 to 35,699,832; highest withheld votes were for Frank Huttle III (1,216,630) and Frank W. Baier (1,011,078).
• · Proposal 2 (2026 Equity Incentive Plan): 34,424,591 For, 1,648,967 Against, 57,343 Abstentions.
• · Proposal 3 (Advisory Say-on-Pay): 34,932,239 For, 774,603 Against, 424,059 Abstentions.
• · Proposal 4 (Ratification of Auditors): 41,871,092 For, 377,047 Against, 44,972 Abstentions — no broker non-votes as this is a routine matter.
• · Elizabeth Magennis was previously Executive Vice President of the Registrant and President of ConnectOne Bank; she will continue as President of the Bank and as a director of both entities.
• · Frank Sorrentino relinquished the President title but remains Chairman and CEO.

20-05-2026

Shore Bancshares held its annual meeting on May 20, 2026, where shareholders elected five directors for three-year terms, approved non-binding executive compensation, and ratified Crowe LLP as auditor for FY2026. All proposals passed with majority support, though director elections had notable votes against certain nominees.

• · Michael B. Adams received 23,396,968 votes for and 1,060,701 against; James M. Burke received 24,176,173 for and 224,544 against; Louis P. Jenkins, Jr. received 23,241,285 for and 1,217,414 against; David S. Jones received 22,287,650 for and 2,110,133 against; Dawn M. Willey received 23,238,686 for and 1,236,951 against.
• · Non-binding executive compensation approval: 23,842,167 for, 593,669 against, 80,475 abstentions.
• · Ratification of Crowe LLP: 28,335,126 for, 10,230 against, 48,666 abstentions.

20-05-2026

Biodesix, Inc. held its 2026 annual meeting on May 19, 2026, where stockholders elected two Class III directors (Jean Franchi and Hany Massarany), approved non-binding advisory votes on executive compensation and the frequency of such votes (one year), and ratified KPMG LLP as the independent auditor for fiscal 2026. All proposals passed with strong support, though director Jean Franchi received a notable 721,832 abstentions, and the advisory vote on compensation frequency saw 777,394 votes for a three-year cycle against management's recommended one-year frequency.

• · Director Jean Franchi received 6,191,974 votes for, 0 against, 721,832 abstentions, and 1,784,659 broker non-votes.
• · Director Hany Massarany received 6,847,586 votes for, 0 against, 66,220 abstentions, and 1,784,659 broker non-votes.
• · Advisory vote on executive compensation: 6,618,755 for, 283,474 against, 11,577 abstentions, 1,784,659 broker non-votes.
• · Advisory vote on frequency of compensation votes: 6,114,363 for one year, 4,393 for two years, 777,394 for three years, 17,656 abstentions, 1,784,659 broker non-votes.
• · Ratification of KPMG LLP: 8,695,977 for, 59 against, 2,429 abstentions, 0 broker non-votes.
• · Record date for the meeting was March 23, 2026, with 10,107,219 shares outstanding.

20-05-2026

BlackRock Monticello Debt Real Estate Investment Trust filed an amendment (Form 10-Q/A) to its Q1 2026 quarterly report solely to include previously omitted Iran Threat Reduction and Syria Human Rights Act disclosure (Exhibit 99.1) and related certifications. The amendment does not change any financial results or reflect events after the original filing date. As of May 5, 2026, the company had 347,110 Class E, 5,600,925 Class F-I, and 2,745,561 Class F-S common shares outstanding, with no shares of other classes outstanding.

• · The amendment was filed on May 20, 2026, to add Exhibit 99.1 (Section 13(r) disclosure) and updated certifications under Rule 13a-14(a)/15d-14(a).
• · No financial statements are included in this amendment; it does not amend any disclosure under Items 307 or 308 of Regulation S-K.
• · The company is a non-accelerated filer, smaller reporting company, and emerging growth company.

20-05-2026

Banco Santander and Webster Financial Corporation held a joint 'Walk the Walls' integration session to prepare for the acquisition's closing in the second half of 2026. The teams reviewed over 250 dependencies and 225 milestones, made nearly 100 updates to workplans, and held three cross-functional breakout sessions. While the filing highlights strong collaboration and momentum, it also notes significant risks including potential delays in closing, integration difficulties, and the possibility that cost savings and synergies may not be fully realized or may take longer than anticipated.

• · The acquisition is expected to close in the second half of 2026.
• · The registration statement on Form F-4 was declared effective on April 22, 2026.
• · Webster commenced mailing the definitive proxy statement/prospectus to its stockholders on April 24, 2026.
• · The filing includes extensive risk factors, including potential failure to obtain regulatory approvals, integration difficulties, and adverse market reactions.

20-05-2026

PEDEVCO CORP. entered into a Third Amendment to its Credit Agreement with Citibank, N.A. on May 19, 2026, increasing the borrowing base and elected commitment amount from $120 million to $125 million. The amendment also rescheduled the next borrowing base redetermination to July 1, 2026. No negative or flat performance metrics were reported in this filing.

• · The Third Amendment was entered into on May 19, 2026, and the filing was made on May 20, 2026.
• · The next borrowing base redetermination is scheduled for on or about July 1, 2026.
• · The Third Amendment constitutes the redetermination originally scheduled for December 1, 2025.
• · The Credit Agreement was originally dated October 31, 2025, and has been amended three times (First Amendment on December 2, 2025; Second Amendment on May 5, 2026; Third Amendment on May 19, 2026).

20-05-2026

Bayview Acquisition Corp reported a net loss of $367,344 for Q1 2026, compared to net income of $143,915 in Q1 2025, driven by higher formation and operating costs ($471,513 vs $270,459). Total assets increased to $12.14M from $11.81M, while accumulated deficit widened to $6.14M. The company continues to seek a business combination.

• · Basic and diluted net income per share for redeemable shares was $0.03 in Q1 2026 vs $0.09 in Q1 2025.
• · Basic and diluted net loss per share for non-redeemable shares was $(0.23) in Q1 2026 vs $(0.12) in Q1 2025.
• · Total liabilities increased to $6.26M as of March 31, 2026 from $5.57M as of December 31, 2025.
• · Cash provided by operating activities was $6,058 in Q1 2026 vs cash used of $41,019 in Q1 2025.
• · The company had $12.01M in investments held in trust account as of March 31, 2026.
• · Promissory notes – extension increased to $1.925M from $1.775M.

20-05-2026

TrustCo Bank Corp NY declared a quarterly cash dividend of $0.38 per share ($1.52 annualized), payable on July 1, 2026 to shareholders of record on June 5, 2026. The dividend was announced on May 20, 2026, following a Board decision on May 19, 2026.

• · Dividend payable on July 1, 2026
• · Record date: June 5, 2026
• · Board declared dividend on May 19, 2026

20-05-2026

Bally's Corporation held its 2026 Annual Meeting on May 19, 2026, with 44,568,505 shares represented out of 48,743,136 outstanding. Shareholders elected Jeffrey W. Rollins and George T. Papanier as directors, ratified Deloitte & Touche as auditor, approved executive compensation on an advisory basis, and approved the amended 2021 Equity Incentive Plan. All proposals passed with strong support, with the lowest 'for' percentage being 95.5% for the equity plan.

• · Broker non-votes were 1,515,798 for all director elections and proposals 1, 3, and 4.
• · Proposal 2 (auditor ratification) had no broker non-votes; 74,706 against and 3,678 abstentions.
• · Proposal 3 (say-on-pay) had 398,072 against and 17,315 abstentions.
• · Proposal 4 (equity plan) had 422,931 against and 19,901 abstentions.

20-05-2026

Golden Minerals reported a net loss of $0.6 million for Q1 2026, an improvement from a $1.2 million loss in Q1 2025, driven by lower administrative expenses and a small income from discontinued operations. However, cash and cash equivalents fell to $0.9 million from $1.3 million (plus $0.5 million restricted) at year-end 2025, and the company stated it does not have sufficient resources to meet expected cash needs for twelve months beyond the filing date. Subsequent to quarter end, the company completed the sale of its Mexican subsidiary Minera William for $1.2 million and entered a private placement for expected gross proceeds of ~$856,000, which together are expected to fund operations into early 2027.

• · The company controls 67% of the Desierto Project in Salta Province, Argentina.
• · In January 2025, the company exercised its option to earn a 60% interest in the Sand Canyon Project in Nevada.
• · No drilling was planned at Sand Canyon during Q1 2026; the company reviewed historical exploration data.
• · The private placement of 3,740,000 shares at $0.2290 per share is subject to TSX approval and expected to close on or around May 20, 2026.
• · The company's only near-term opportunities to generate cash flow are from sale of additional assets, equity, or external financing.
• · The company is evaluating alternatives including potential sale of the company, seeking buyers or partners for remaining assets, or obtaining equity or other external financing.

20-05-2026

Rigel Pharmaceuticals held its 2026 Annual Meeting on May 14, 2026, where stockholders approved amendments to the 2018 Equity Incentive Plan (adding 500,000 shares) and the 2000 Employee Stock Purchase Plan (adding 360,000 shares). Directors Alison Hannah, Walter Moos, and Raul Rodriguez were elected, and stockholders ratified Ernst & Young as independent auditor for fiscal 2026. The say-on-pay advisory vote was also approved.

• · The Amended 2018 Plan and Amended ESPP became effective immediately upon stockholder approval.
• · Broker non-votes were 3,406,029 for all director elections and most proposals, except ratification of Ernst & Young which had no broker non-votes.
• · The say-on-pay proposal received 9,013,480 for, 1,291,609 against, and 416,316 abstentions.

20-05-2026

First Internet Bancorp held its 2026 annual meeting of shareholders on May 18, 2026. All eight director nominees were elected, and shareholders approved the advisory 'Say-on-Pay' executive compensation vote. While the ratification of Forvis Mazars, LLP as independent auditor passed overwhelmingly with 95.9% of votes cast in favor, the Say-on-Pay vote showed notable opposition with 17.3% of votes cast against and 0.5% abstaining.

20-05-2026

Schrodinger, Inc. announced on May 18, 2026 that Mannix Aklian ceased as Chief Commercial Officer, Global Head of Software Sales and Marketing, effective immediately. Paul Davie, the former EVP of Sales, returns as interim replacement while a permanent search is conducted. The company reaffirmed its full-year and Q2 2026 financial and operational guidance from its May 5, 2026 earnings release.

• · The departure was effective immediately on May 18, 2026.
• · Paul Davie previously served as Executive Vice President, Sales at Schrodinger.
• · The company is conducting a search for a permanent replacement for the Chief Commercial Officer role.
• · The company reaffirmed its full-year and Q2 2026 guidance originally provided on May 5, 2026.